KURT IMHOF

Support repeal of R&D Amortization (S866 and HR 2673) to reduce tax liability for small/growing life sciences companies. HR 2673 and S866 titled "American Innovation and R&D Competitiveness Act of 2023. Support the Orphan Drug Tax Credit and oppose proposals to further alter it, or the Orphan Drug Act.

Support repeal of R&D Amortization (S866 and HR 2673) to reduce tax liability for small/growing life sciences companies. HR 2673 and S866 titled "American Innovation and R&D Competitiveness Act of 2023. Support the Orphan Drug Tax Credit and oppose proposals to further alter it, or the Orphan Drug Act.

Support reintroduction of the VALID Act (previously HR 4128). Support the PASTEUR Act to incentivize the development of novel antimicrobial medicines. (S1355 and HR2490) Support PAHPA Reauthorization and stress the importance of investing in public health and pandemic preparedness.

Support reintroduction of the VALID Act (previously HR 4128). Support the PASTEUR Act to incentivize the development of novel antimicrobial medicines. (S1355 and HR2490) Support PAHPA Reauthorization and stress the importance of investing in public health and pandemic preparedness.

Support policies, like the HELP Copays (HR 830) Act, that increase access to medicines.

Support policies, like the HELP Copays (HR 830) Act, that increase access to medicines.

Support reintroduction of the VALID Act (previously HR 4128). Support the PASTEUR Act to incentivize the development of novel antimicrobial medicines. (S1355 and HR2490) Support PAHPA Reauthorization and stress the importance of investing in public health and pandemic preparedness.

Support reintroduction of the VALID Act (previously HR 4128). Support the PASTEUR Act to incentivize the development of novel antimicrobial medicines. (S1355 and HR2490) Support PAHPA Reauthorization and stress the importance of investing in public health and pandemic preparedness.

Support repeal of R&D Amortization (S866 and HR 2673) to reduce tax liability for small/growing life sciences companies. HR 2673 and S866 titled "American Innovation and R&D Competitiveness Act of 2023. Support the Orphan Drug Tax Credit and oppose proposals to further alter it, or the Orphan Drug Act.

Support repeal of R&D Amortization (S866 and HR 2673) to reduce tax liability for small/growing life sciences companies. HR 2673 and S866 titled "American Innovation and R&D Competitiveness Act of 2023. Support the Orphan Drug Tax Credit and oppose proposals to further alter it, or the Orphan Drug Act.

Share our concerns and support with PA congressional offices on implementation of Medicare Part D and B provisions in the Inflation Reduction Act (e.g. negotiations in Part D, inflationary rebate penalty, out-of-pocket cap for seniors, and vaccine cost sharing). Urge legislators to support legislation that aligns breakthrough device designation at e FDA with a coverage pathway at CMS - HR 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Share our concerns and support with PA congressional offices on implementation of Medicare Part D and B provisions in the Inflation Reduction Act (e.g. negotiations in Part D, inflationary rebate penalty, out-of-pocket cap for seniors, and vaccine cost sharing). Urge legislators to support legislation that aligns breakthrough device designation at e FDA with a coverage pathway at CMS - HR 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Express concern with CMS via comment letter on their TCET rule implementation Express concern with CMS MAC recent LCD determination to eliminate Medicare coverage of advanced wound treatment products.

Share our concerns and support with PA congressional offices on implementation of Medicare Part D and B provisions in the Inflation Reduction Act (e.g. negotiations in Part D, inflationary rebate penalty, out-of-pocket cap for seniors, and vaccine cost sharing). Urge legislators to support legislation that aligns breakthrough device designation at e FDA with a coverage pathway at CMS - HR 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Share our concerns and support with PA congressional offices on implementation of Medicare Part D and B provisions in the Inflation Reduction Act (e.g. negotiations in Part D, inflationary rebate penalty, out-of-pocket cap for seniors, and vaccine cost sharing). Urge legislators to support legislation that aligns breakthrough device designation at FDA with a coverage pathway at CMS - HR 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Support reintroduction of the VALID Act (previously HR 4128). Support the PASTEUR Act to incentivize the development of novel antimicrobial medicines. (S1355 and HR2490)

Support reintroduction of the VALID Act (previously HR 4128). Support the PASTEUR Act to incentivize the development of novel antimicrobial medicines. (S1355 and HR2490) Support PAHPA Reauthorization and stress the importance of investing in public health and pandemic preparedness.

Support repeal of R&D Amortization (S866 and HR 2673) to reduce tax liability for small/growing life sciences companies. HR 2673 and S866 titled "American Innovation and R&D Competitiveness Act of 2023. Support the Orphan Drug Tax Credit and oppose proposals to further alter it, or the Orphan Drug Act.

Support reintroduction of the VALID Act (previously HR 4128). Support the PASTEUR Act to incentivize the development of novel antimicrobial medicines. (S1355 and HR2490) Support PAHPA Reauthorization and stress the importance of investing in public health and pandemic preparedness.

Support reintroduction of the VALID Act (previously HR 4128)

Support reintroduction of the VALID Act (previously HR 4128). Support the PASTEUR Act to incentivize the development of novel antimicrobial medicines. (S1355 and HR2490)

Support reintroduction of the VALID Act (previously HR 4128)

Support policies, like the HELP Copays (HR 830) Act, that increase access to medicines.

Support policies, like the HELP Copays (HR 830) Act, that increase access to medicines.

Support reintroduction of the VALID Act (previously HR 4128). Support the PASTEUR Act to incentivize the development of novel antimicrobial medicines. (S1355 and HR2490)

Support reintroduction of the VALID Act (previously HR 4128). Support the PASTEUR Act to incentivize the development of novel antimicrobial medicines. (S1355 and HR2490) Support PAHPA Reauthorization and stress the importance of investing in public health and pandemic preparedness.

Support repeal of R&D Amortization (S866) to reduce tax liability for small/growing life sciences companies. Support the Orphan Drug Tax Credit and oppose proposals to further alter it, or the Orphan Drug Act.

Support repeal of R&D Amortization (S866) to reduce tax liability for small/growing life sciences companies. Support the Orphan Drug Tax Credit and oppose proposals to further alter it, or the Orphan Drug Act.

Support repeal of R&D Amortization (S866 and HR 2673) to reduce tax liability for small/growing life sciences companies. HR 2673 and S866 titled "American Innovation and R&D Competitiveness Act of 2023. Support the Orphan Drug Tax Credit and oppose proposals to further alter it, or the Orphan Drug Act.

Support repeal of R&D Amortization (S866) to reduce tax liability for small/growing life sciences companies. Support the Orphan Drug Tax Credit and oppose proposals to further alter it, or the Orphan Drug Act.

Advocated for co-sponsorship of DISARM and PASTEUR Acts to incentivize novel AMR medicines among PA congressional delegation members and the Department of Health and Human Services Expressed concern on government price settings in legislation, such as H.R. 3 - in particular removing the non-interference clause in Medicare Part D and/or pegging medicine prices to those paid in foreign countries. Expressed support for proposals that limit out-of-pocket costs for patients. Wrote to CMS with the support of several medical device and diagnostic members in support of the CMS Final Rule on Medicare Coverage of Innovative Technology and Definition of Reasonable and Necessary to several PA delegation members.

Continued to advocated for DISARM and PASTEUR Acts to incentivize novel AMR medicines among PA congressional delegation members and the Department of Health and Human Services Expressed concern on government price settings in legislation, such as H.R. 3 - in particular removing the non-interference clause in Medicare Part D and/or pegging medicine prices to those paid in foreign countries. Opposed efforts to include this policy in any kind of large budget reconciliation package. Expressed support for proposals that limit out-of-pocket costs for patients. Asked several members of the Pennsylvania delegation to sign on to legislation that would align the breakthrough designation of medical technologies with reimbursement by CMS - an issue important to our medical device and diagnostic members.

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Discussed drug pricing policies, like those put forth in H.R. 3, and their affect on innovation including Medicare negotiation, international reference pricing, PBM rebates and how the prescription medicine supply chain is setup. Advocated for PA congressional delegation members to sign-on to a letter regarding co-pay accumulator rules changes. Participated in a webinar and sent background information to the Pennsylvania congressional delegation on the life sciences community's response to COVID-19. Expressed concern over the Administration's efforts to enact "Buy American" policies that could disrupt the global supply chain utilized by biopharmaceutical and medical technology businesses.

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements

Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Strong IP/Patent protections - e.g. Stronger Patents Act, S.2082 Protecting Medicare Part D and Part B - e.g. HR19, Lower Costs, More Cures Act Increases in NIH funding Support legislation that improves public health - e.g. S1712 and HR4100, the DISARM Act Access to medical technologies - e.g. Ensuring Patient Access to Critical Breakthrough Products Act, HR5333 Protecting the safety of the drug supply chain Encourage collaborative relationships between the industry and the FDA, e.g. User Fee Agreements